Asset Details
Do you wish to reserve the book?
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Do you wish to request the book?
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
2003
Overview
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Gerald F. Watts 1 ,
P. Hugh R. Barrett 1 ,
Juying Ji 1 ,
Adrian P. Serone 2 ,
Dick C. Chan 1 ,
Kevin D. Croft 1 ,
Franziska Loehrer 2 and
Anthony G. Johnson 2
1 Lipoprotein Research Unit, Department of Medicine, University of Western Australia, the West Australian Institute for Medical
Research, Perth, Western Australia
2 James Lance GlaxoSmithKline Medicines Research Unit, Prince of Wales Hospital, Sydney, Australia
Abstract
The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100
(apoB) metabolism that may collectively accelerate atherosclerosis. The effects of atorvastatin (40 mg/day) and micronised
fenofibrate (200 mg/day) on the kinetics of apoAI and apoB were investigated in a controlled cross-over trial of 11 dyslipidemic
men with the metabolic syndrome. ApoAI and apoB kinetics were studied following intravenous d 3 -leucine administration using gas-chromatography mass spectrometry with data analyzed by compartmental modeling. Compared
with placebo, atorvastatin significantly decreased ( P < 0.001) plasma concentrations of cholesterol, triglyceride, LDL cholesterol, VLDL apoB, intermediate-density lipoprotein
(IDL) apoB, and LDL apoB. Fenofibrate significantly decreased ( P < 0.001) plasma triglyceride and VLDL apoB and elevated HDL 2 cholesterol ( P < 0.001), HDL 3 cholesterol ( P < 0.01), apoAI ( P = 0.01), and apoAII ( P < 0.001) concentrations, but it did not significantly alter LDL cholesterol. Atorvastatin significantly increased ( P < 0.002) the fractional catabolic rate (FCR) of VLDL apoB, IDL apoB, and LDL apoB but did not affect the production of apoB
in any lipoprotein fraction or in the turnover of apoAI. Fenofibrate significantly increased ( P < 0.01) the FCR of VLDL, IDL, and LDL apoB but did not affect the production of VLDL apoB. Relative to placebo and atorvastatin,
fenofibrate significantly increased the production ( P < 0.001) and FCR ( P = 0.016) of apoAI. Both agents significantly lowered plasma triglycerides and apoCIII concentrations, but only atorvastatin
significantly lowered ( P < 0.001) plasma cholesteryl ester transfer protein activity. Neither treatment altered insulin resistance. In conclusion,
these differential effects of atorvastatin and fenofibrate on apoAI and apoB kinetics support the use of combination therapy
for optimally regulating dyslipoproteinemia in the metabolic syndrome.
Footnotes
Address correspondence and reprint requests to Associate Professor G.F. Watts, University Department of Medicine, Royal Perth
Hospital, Box X2213 GPO, Perth, WA 6847, Australia. E-mail: gfwatts{at}cyllene.uwa.edu.au
Received for publication 28 August 2002 and accepted in revised form 2 December 2002.
P.H.R.B. is a Career Development Fellow of the National Heart Foundation, and A.P.S., F.L., and A.G.J. are employees of GlaxoSmithKline.
apoAI, apolipoprotein AI; apoB, apolipoprotein B-100; CETP, cholesteryl ester transfer protein; FCR, fractional catabolic
rate; GCMS, gas chromatography; HOMA, homeostasis model assessment; HMG, hydroxymethylglutaryl; IDL, intermediate-density
lipoprotein; LCAT, lecithin cholesterol acyltransferase; PPAR, peroxisome proliferator–activated receptor; PR, production
rate.
DIABETES
Publisher
American Diabetes Association
